Focus on care plan optimization and prevention
Through a patient-facing app, patients can communicate with their dedicated clinical care team via text, talk or video call. With improved engagement, patients can better understand their conditions and make decisions to manage disease progression—resulting in improved health outcomes for patients and lower costs for providers and payers. The Biofourmis Care solution seeks to prevent clinical deterioration by remotely optimizing medication regimens in accordance with evidence-based guidelines, facilitating lifestyle modifications, and overcoming obstacles to care plan adherence.
Ad Statistics
Times Displayed: 125136
Times Visited: 7236 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
“Biofourmis Care completes our continuum-wide offering that providers and payers can leverage to optimize care plans,” Dr. Majmudar said. “The solution is a gamechanger due to its ability to prevent or quickly detect clinical deterioration for earlier interventions and better outcomes.”
About Biofourmis
Biofourmis is a fast-growing global health technology company that is focused on leveraging software and data science to deliver virtual care and develop novel digital therapies. The company’s robust care management platform, Care@Home, enables remote disease management across a range of medical conditions for acute, post-acute and chronic care. The solution utilizes medical-grade wearables to continuously collect patient data, which is analyzed by Biovitals®, Biofourmis’ highly sophisticated, clinically validated AI-powered predictive analytics engine. With support from Biofourmis’ in-house clinical care team, payers and providers can leverage the solution to predict clinical deterioration in advance of a critical event—which enables earlier interventions for better outcomes and cost savings. Likewise, the company discovers, develops and delivers clinically validated digital therapeutics. These monotherapies or “pill plus” prescription therapeutics support payers and providers in improving patients’ lives while reducing healthcare utilization and associated costs. For more information, visit: www.biofourmis.com; and follow the company on LinkedIn and Twitter.
Back to HCB News
